Together, our studies provide a basis for mechanistic understanding and inhibition of the dominant-negative effect of DNMT3A R882 mutations, shedding light on the development of an effective therapeutic strategy against AML and other DNMT3A R882 mutation-associated diseases. Here, DNMT3A is linked to acute myeloid leukemia.